Zentalis Pharmaceuticals, Inc. Operating Cash Flow
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Operating Cash Flow of -$70.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$37.24M.
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$32.96M.
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$30.94M.
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$26.96M.
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$125.25M.
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$170.86M.
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$207.82M.
- Zentalis Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$163.75M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$37.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$70.19M 10-Q · filed 2026-08-06 | -$101.13M derived: sum of 3 quarters · filed 2026-08-06 | -$128.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$32.96M 10-Q · filed 2026-05-12 | -$63.90M derived: sum of 2 quarters · filed 2026-05-12 | -$90.86M derived: sum of 3 quarters · filed 2026-05-12 | -$125.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$30.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$57.90M derived: sum of 2 quarters · filed 2026-03-26 | -$92.61M derived: sum of 3 quarters · filed 2026-08-06 | -$125.25M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$26.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$61.67M derived: sum of 2 quarters · filed 2026-08-06 | -$94.31M 10-Q · filed 2025-11-10 | -$134.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$34.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$67.34M 10-Q · filed 2026-08-06 | -$107.05M derived: sum of 3 quarters · filed 2026-08-06 | -$151.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$32.64M 10-Q · filed 2026-05-12 | -$72.34M derived: sum of 2 quarters · filed 2026-05-12 | -$116.38M derived: sum of 3 quarters · filed 2026-05-12 | -$151.52M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$39.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$83.75M derived: sum of 2 quarters · filed 2026-03-26 | -$118.89M derived: sum of 3 quarters · filed 2026-03-26 | -$170.86M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$44.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$79.18M derived: sum of 2 quarters · filed 2025-11-10 | -$131.16M 10-Q · filed 2025-11-10 | -$171.76M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | -$35.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$87.11M 10-Q · filed 2025-08-06 | -$127.71M derived: sum of 3 quarters · filed 2026-03-26 | -$166.38M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | -$51.97M 10-Q · filed 2025-05-14 | -$92.57M derived: sum of 2 quarters · filed 2026-03-26 | -$131.24M derived: sum of 3 quarters · filed 2026-03-26 | -$210.51M derived: sum of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | -$40.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$79.26M derived: sum of 2 quarters · filed 2026-03-26 | -$158.54M derived: sum of 3 quarters · filed 2026-03-26 | -$207.82M 10-K · filed 2026-03-26 |
| 2023-09-30 | -$38.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$117.94M derived: sum of 2 quarters · filed 2024-11-12 | -$167.22M 10-Q · filed 2024-11-12 | -$204.55M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | -$79.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$128.56M 10-Q · filed 2024-08-09 | -$165.89M derived: sum of 3 quarters · filed 2025-03-26 | -$199.09M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | -$49.28M 10-Q · filed 2024-05-07 | -$86.61M derived: sum of 2 quarters · filed 2025-03-26 | -$119.81M derived: sum of 3 quarters · filed 2025-03-26 | -$162.84M derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | -$37.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$70.53M derived: sum of 2 quarters · filed 2025-03-26 | -$113.56M derived: sum of 3 quarters · filed 2025-03-26 | -$163.75M 10-K · filed 2025-03-26 |
| 2022-09-30 | -$33.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$76.23M derived: sum of 2 quarters · filed 2023-11-06 | -$126.42M 10-Q · filed 2023-11-06 | -$163.44M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$43.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$93.22M 10-Q · filed 2023-08-09 | -$130.24M derived: sum of 3 quarters · filed 2024-02-27 | -$163.73M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$50.20M 10-Q · filed 2023-05-10 | -$87.22M derived: sum of 2 quarters · filed 2024-02-27 | -$120.71M derived: sum of 3 quarters · filed 2024-02-27 | -$166.82M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$37.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$70.51M derived: sum of 2 quarters · filed 2024-02-27 | -$116.62M derived: sum of 3 quarters · filed 2024-02-27 | -$154.09M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$33.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$79.60M derived: sum of 2 quarters · filed 2022-11-09 | -$117.07M 10-Q · filed 2022-11-09 | -$144.43M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$46.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$83.58M 10-Q · filed 2022-08-09 | -$110.94M derived: sum of 3 quarters · filed 2023-03-01 | -$131.50M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$37.47M 10-Q · filed 2022-05-05 | -$64.83M derived: sum of 2 quarters · filed 2023-03-01 | -$85.39M derived: sum of 3 quarters · filed 2023-03-01 | -$107.42M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$27.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$47.92M derived: sum of 2 quarters · filed 2023-03-01 | -$69.95M derived: sum of 3 quarters · filed 2023-03-01 | -$86.83M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$20.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$42.60M derived: sum of 2 quarters · filed 2021-11-10 | -$59.47M 10-Q · filed 2021-11-10 | -$72.66M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$22.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$38.90M 10-Q · filed 2021-08-12 | -$52.09M derived: sum of 3 quarters · filed 2022-02-24 | -$62.08M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$16.87M 10-Q · filed 2021-05-17 | -$30.06M derived: sum of 2 quarters · filed 2022-02-24 | -$40.05M derived: sum of 3 quarters · filed 2022-02-24 | -$47.01M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$13.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$23.18M derived: sum of 2 quarters · filed 2022-02-24 | -$30.14M derived: sum of 3 quarters · filed 2022-02-24 | -$39.14M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$9.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$16.95M derived: sum of 2 quarters · filed 2020-11-09 | -$25.95M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | -$6.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$15.96M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | -$9.01M 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |